1. Home
  2. QTTB vs PASG Comparison

QTTB vs PASG Comparison

Compare QTTB & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$3.05

Market Cap

25.1M

Sector

Health Care

ML Signal

HOLD

PASG

Passage Bio Inc.

HOLD

Current Price

$9.90

Market Cap

29.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QTTB
PASG
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
29.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
QTTB
PASG
Price
$3.05
$9.90
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$7.33
$34.50
AVG Volume (30 Days)
9.0M
46.5K
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$5.12
52 Week High
$6.37
$20.20

Technical Indicators

Market Signals
Indicator
QTTB
PASG
Relative Strength Index (RSI) 53.39 59.12
Support Level $3.06 $8.23
Resistance Level $3.96 $10.71
Average True Range (ATR) 0.53 0.87
MACD 0.01 0.11
Stochastic Oscillator 24.37 74.04

Price Performance

Historical Comparison
QTTB
PASG

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: